Encapsulation of anticancer medications within liposomes is a technique to facilitate drug transportation to the target and accumulation in tumors. Sato and colleagues evaluated the tolerability and efficacy of a liposomal formulation of eribulin (E7389-LF) in patients with advanced solid tumors. E7389-LF was well tolerated overall, and 4/21 of the patients treated achieved a partial response. Endothelial cell, vasculature, and immune-related biomarkers were increased after treatment. Thus E7389-LF may influence tumor vascular remodeling. These findings support further evaluation of E7389-LF for advanced solid tumors. Expansion cohorts are ongoing to evaluate the safety, efficacy, and pharmacodynamics of E7389-LF 2.0 mg/m2 every 3 weeks in specific tumor types.
Molecular profiles in solid tumors dynamically evolve in response to endogenous and exogenous pressures. Lodrini and colleagues noninvasively monitored high-risk neuroblastoma evolution using droplet digital PCR assessing MYCN and ALK oncogene status in longitudinally collected biosamples to explore the clinical value of total...
